Cervical cancer, a preventable and treatable disease, remains a significant health issue globally, particularly affecting women in lower-income countries. Each year, approximately 600,000 new cases are diagnosed, leading to around 340,000 deaths. The HPV vaccine plays a crucial role in reducing these alarming statistics, especially as women in lower-income countries are three times more likely to develop cervical cancer and six times more likely to die from it compared to their counterparts in wealthier nations.
The World Health Organization (WHO) has established ambitious targets known as the 90-70-90 goals for 2030, aiming to eliminate cervical cancer as a public health threat. A key component of this initiative is ensuring that 90% of girls are vaccinated against HPV by age 15. This target is particularly critical given that more than 90% of cervical cancer deaths occur in low- and middle-income countries, where access to healthcare and preventive measures is often limited.
Recent studies, including one conducted by PATH in collaboration with immunization program managers, have assessed the operational context and estimated the ongoing costs of HPV vaccine delivery. This study generated valuable evidence on implementing a two-dose HPV vaccination schedule in six countries: Ethiopia, Guyana, Rwanda, Senegal, Sri Lanka, and Uganda. Notably, Rwanda has achieved vaccination coverage close to 98%, setting a benchmark for other nations striving to meet the WHO’s targets.
Despite the progress, the tragedy lies in the inequality behind cervical cancer’s impact. “Cervical cancer should no longer be killing women,” advocates emphasize, highlighting the need for increased focus and financing for cervical cancer elimination efforts. The WHO’s targets also include ensuring that 90% of women are screened by age 35 and again by age 45, along with treating 90% of women with cervical disease. These goals are essential for reducing the incidence and mortality rates associated with this disease.
The first World Cervical Cancer Elimination Day was marked in November 2025, symbolizing a global commitment to tackling this preventable disease. If successful, the elimination of cervical cancer would represent a historic achievement, marking the first time humanity has eradicated a cancer as a public health threat. The tools and strategies are available, but the window for action is limited.
As countries work towards these ambitious targets, the focus must remain on equitable access to the HPV vaccine and screening programs. The disparity in cervical cancer outcomes between high-income and low-income countries underscores the urgent need for global health initiatives to prioritize cervical cancer elimination. “Cervical cancer elimination must become a financing priority,” experts argue, emphasizing that without adequate funding and resources, the goals set for 2030 may remain out of reach.
While the path forward is promising, uncertainties remain regarding the full implementation of these strategies across diverse healthcare systems. Details remain unconfirmed as countries navigate the complexities of vaccine distribution and public health education. However, the commitment to reducing cervical cancer’s burden is stronger than ever, with the HPV vaccine at the forefront of this critical public health initiative.